CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates Feb 21, 2017
CohBar, Inc.’s CEO Simon Allen to Present at the 2017 BIO CEO & Investor Conference in New York Feb 9, 2017
CohBar, Inc. Announces Expiration of Warrants and Reports Aggregate Proceeds from Warrant Exercises Jan 11, 2017
CohBar, Inc.’s CEO Simon Allen to Present at the 9th Annual Biotech Showcase in San Francisco Jan 10, 2017
CohBar, Inc. Continues Exploration of Mitochondrial Genome and Expansion of Its IP Portfolio with Filing of 29 New Provisional Patents Dec 6, 2016